1 – 10 of 245
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
LEVELS OF IL-6 AND OTHER INFLAMMATORY PROTEINS IN EARLY RA PREDICT JOINT DAMAGE PROGRESSION OVER 5 YEARS
(
- Contribution to journal › Published meeting abstract
-
Mark
Flares after hydroxychloroquine reduction or discontinuation : results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
(
- Contribution to journal › Article
-
Mark
Development and validation of a patient-reported outcome measure for systemic sclerosis : the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire
(
- Contribution to journal › Article
-
Mark
Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus : data from the COVID-19 Global Rheumatology Alliance
(
- Contribution to journal › Article
- 2020
-
Mark
EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies
(
- Contribution to journal › Article
-
Mark
Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies
(
- Contribution to journal › Letter
-
Mark
High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus
(
- Contribution to journal › Article
- 2019
-
Mark
“TO REGAIN ONE’S HEALTH” – PATIENTS’ PREFERENCES OF TREATMENT OUTCOMES IN EARLY RHEUMATOID ARTHRITIS – A QUALITATIVE STUDY
(
- Contribution to journal › Published meeting abstract
-
Mark
PREDICTORS OF EROSION AND JOINT SPACE NARROWING PROGRESSION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
(
- Contribution to journal › Published meeting abstract
-
Mark
Tight control management of early RA achieves more patients in remission at 6 months and improves pain, function and Fatigue at 24 months compared to a control group
(
- Contribution to journal › Published meeting abstract